Most Read Articles
Fiel Soliven, 18 Mar 2015
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
01 Feb 2016
Long-term ezetimibe improves lipid metabolism in dyslipidaemic patients with hepatobiliary disease, based on a study.
01 Feb 2016
Use of gadoxetate disodium for functional MRI can obtain useful data on hepatobiliary diseases, an article states.
Tristan Manalac, 14 Sep 2017
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.

Sphingosine-1-phosphate levels tied to 3-month, 1-year mortality in end-stage liver disease

01 Apr 2017

Prognosis in end-stage liver disease has highly significant association with plasma levels of sphingosine-1-phosphate (S1P), such that patients with low circulating S1P levels have lower 3-month and 1-year survival compared with those who have high S1P levels, a new study shows.

The study included 95 citrated plasma samples from patients who were assessed for orthotopicliver transplantation (OLT). Those who were receiving vitamin K antagonists or rivaroxaban as oral anti-coagulation therapies were excluded.

Hydrophilic interaction chromatography and liquid chromatography-mass spectrometry were used to process and quantify the levels of S1P, sphinganine-1-phosphate (SA1P) and sphingosine (SPH).

At the 3-month and 1-year follow-up, 9.5 (n=9)and 20 percent(n=19) of patients, respectively, died without OLT. Moreover, 10.5 percent (n=10) received OLT within 1 year.

The survival ratespredicted by S1P were 93.8, 83.1 and 57.1 percent for the third, second and first analyte concentration tertiles, respectively. Comparing the first to the second and third tertiles, the hazard ratios (HR) were 2.99 (95 percent CI,1.05 to 8.49; p=0.04)and 8.87 (1.98 to 39.78; p=0.004), respectively.

Survival rates for SA1P were 94.4, 80.2 and 64.5 percent for the third, second and first analyte concentration tertiles respectively. Only the comparison of the first to the third tertile yielded a significant HR (4.50; 1.24 to 16.40; p=0.023). No significant HRs were calculated for SPH.

Moreover, only S1P was the significant predictor of 3-month (HR, 0.94; 0.91 to 0.98; p=0.005) and 1-year (HR, 0.96; 0.94 to 0.99; p=0.002) mortality rates, according to the Cox regression analysis.

Finally, after controlling for platelet counts and haemoglobin and SA1P levels, S1P remained a significant predictor of 3-month (p<0.001) and 1-year (p<0.001) mortality, according to multivariate cox regression analysis.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Fiel Soliven, 18 Mar 2015
The connection between prediabetes, diabetes, and risk of hepatocellular carcinoma (HCC) in HBsAg and anti-HCV seronegative patients, as well as the association between fasting glucose and HCC were examined in this study.
01 Feb 2016
Long-term ezetimibe improves lipid metabolism in dyslipidaemic patients with hepatobiliary disease, based on a study.
01 Feb 2016
Use of gadoxetate disodium for functional MRI can obtain useful data on hepatobiliary diseases, an article states.
Tristan Manalac, 14 Sep 2017
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.